Overview

Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium

Status:
Completed
Trial end date:
2009-05-28
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety and efficacy of afamelanotide (previously developed as CUV1647) as adjunctive therapy in patients undergoing photodynamic therapy using porfimer sodium.
Phase:
Phase 2
Details
Lead Sponsor:
Clinuvel Pharmaceuticals Limited
Treatments:
Afamelanotide